Have a feature idea you'd love to see implemented?
Let us know!
SLRX Salarius Pharmaceuticals Inc
Price (delayed)
$1.46
Market cap
$2.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.41
Enterprise value
-$851,091
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment
Highlights
The EPS has soared by 89% YoY and by 41% from the previous quarter
SLRX's net income has surged by 72% year-on-year and by 23% since the previous quarter
SLRX's equity has shrunk by 52% YoY but it is up by 23% QoQ
Key stats
What are the main financial stats of SLRX
Market
Valuations
Earnings
Shares outstanding
1.44M
Market cap
$2.1M
Enterprise value
-$851,091
Price to earnings (P/E)
N/A
Price to book (P/B)
0.72
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$4.99M
EBITDA
-$4.99M
Free cash flow
-$5.29M
Per share
Balance sheet
Liquidity
EPS
-$6.41
Free cash flow per share
-$4.13
Book value per share
$2.03
Revenue per share
$0
TBVPS
$3.01
Total assets
$3.86M
Total liabilities
$934,581
Debt
$328,849
Equity
$2.92M
Working capital
$2.89M
Debt to equity
0.11
Current ratio
4.09
Quick ratio
3.51
Net debt/EBITDA
0.59
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-105.8%
Return on equity
-140.3%
Return on invested capital
N/A
Return on capital employed
-170.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLRX stock price
How has the Salarius Pharmaceuticals stock price performed over time
Intraday
4.29%
1 week
5.8%
1 month
-19.78%
1 year
-72.66%
YTD
-71.92%
QTD
1.39%
Financial performance
How have Salarius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$5.22M
Net income
-$4.99M
Gross margin
N/A
Net margin
N/A
SLRX's net income has surged by 72% year-on-year and by 23% since the previous quarter
The operating income has soared by 72% YoY and by 23% QoQ
Growth
What is Salarius Pharmaceuticals's growth rate over time
Valuation
What is Salarius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.72
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 89% YoY and by 41% from the previous quarter
SLRX's equity has shrunk by 52% YoY but it is up by 23% QoQ
The P/B is 20% higher than the last 4 quarters average of 0.6 and 2.9% higher than the 5-year quarterly average of 0.7
Efficiency
How efficient is Salarius Pharmaceuticals business performance
SLRX's ROE is up by 41% YoY and by 6% from the previous quarter
The ROA is up by 34% YoY and by 4.2% QoQ
Dividends
What is SLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLRX.
Financial health
How did Salarius Pharmaceuticals financials performed over time
The company's total liabilities has shrunk by 60% YoY and by 21% QoQ
Salarius Pharmaceuticals's total assets has shrunk by 54% YoY but it has increased by 9% QoQ
The debt is 89% less than the equity
SLRX's equity has shrunk by 52% YoY but it is up by 23% QoQ
SLRX's debt to equity is up by 38% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.